Luminova Anticipates Reopening of Serra Pàmies Factory and Tripling Sales

Luminova Pharma Group has plans for the Serra Pàmies laboratories. The Latin American pharmaceutical multinational is preparing the facilities located in the town of Reus to significantly transform its operation and production capacity in view of the inspection that the Ministry of Health will carry out during the last quarter of 2024.

To achieve this, Luminova Pharma plans to invest heavily over the next five years, with the aim of expanding and modernizing the plant, which will focus on the production of cardiovascular solutions, diabetes treatments, narcotic and psychotropic products, among many others.

The company’s roadmap will focus on integrating staff to increase the team and transfer knowledge. For the time being, Luminova Pharma Group will follow an integration strategy, which will include expanding the laboratory’s workforce and they plan to have between 250 and 300 employees .

These will include current laboratory employees, members from the Latin American company and new hires, who will be responsible for transferring know-how and product and drug dossiers.

Luminova Pharma Group plans to make the leap from Reus to Europe

The company also announced the opening of a new antibiotics plant that will share space with Serra Pàmies laboratories. The project is planned to start between 2026 and 2028, and will supply both the Spanish and Latin American markets. The first major joint production project under the merged Luminova-Serra Pàmies brand is scheduled for the first quarter of 2025.

In terms of financial targets, Luminova Pharma Group has set a goal of tripling Serra Pàmies sales following investment in advanced technologies, intellectual property transfer and improved manufacturing practices.

According to Kirsten Erichsen, Luminova Pharma’s portfolio development manager, “the idea behind choosing the Serra Pàmies plant was to start with a small facility and take a more gradual approach, ensuring and modernising safety and quality in all operations.”

Once Luminova Pharma Group has established in the Spanish market, the pharma company plans to use this Reus site as a base of operations to make the leap to the rest of Europe, the group announced.

__

(Featured image by stevepb via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us